Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer

NCT02900560 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Epithelial Ovarian Cancer

Interventions

DRUG: CC-486
BIOLOGICAL: Pembrolizumab

Sponsor

Translational Research in Oncology

Collaborators

[object Object]